Business Wire

KIOXIA-CORPORATION

2.11.2022 04:01:36 CET | Business Wire | Press release

Share
Kioxia Presented Image Classification System Deploying Memory-Centric AI with High-capacity Storage at ECCV 2022

Kioxia Corporation, the world leader in memory solutions, has developed an image classification system based on Memory-Centric AI, an AI technology that utilizes high-capacity storage. The system classifies images using a neural network that refers to knowledge stored in external high-capacity storage; this avoids "catastrophic forgetting," one of the major challenges of neural networks, and allows knowledge to be added or updated without the loss of current knowledge. This technology was presented on October 25 at the oral session of European Conference on Computer Vision 2022 (ECCV 2022) in Tel Aviv, one of the top conferences in the field of computer vision[1].

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221101006375/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image classification utilizing high-capacity storage (Graphic: Business Wire)

In conventional AI techniques, neural networks are trained to acquire knowledge by updating parameters called “weights.” Once fully trained, in order to acquire new knowledge a neural network must be either re-trained from the beginning or fine-tuned with new data. The former requires huge amounts of time and consumes significant energy costs, while the latter requires parameters to be updated and faces the catastrophic forgetting problem of losing the knowledge acquired in the past which leads to deterioration of classification accuracy.

To address the issues of cost and accuracy in neural network-based image classification systems, the new solution stores large amounts of image data, labels and image feature maps[2] as knowledge in a high-capacity storage. The neural network then classifies images by referring to that stored knowledge (Figure 1). Using this method, knowledge can be added or updated by adding newly obtained image labels and feature maps to the stored data. As there is no need to re-train or update weights, which may cause “catastrophic forgetting,” image classification can be maintained more accurately.

Furthermore, by using the data referred from the storage when the neural network classifies images, the basis for the classification results can be visualized, which is expected to improve the explainability of AI[3] and alleviate the black-box problem[4], in turn allowing the selective modification of knowledge sources. In addition, by analyzing the referred data, the contribution of each stored data can be evaluated according to the frequency of references.

Guided by its mission of "Uplifting the World with ‘Memory,’" Kioxia will continue to contribute to the development of AI and storage technologies by expanding Memory-Centric AI beyond image classification to other areas and promoting research and development of AI technology utilizing high-capacity storage.

About Memory-Centric AI

Introductory Video: https://youtu.be/lw8XKhviGJc
Memory-Centric AI, Part I: How Kioxia’s Top Engineers Are Developing an AI That Relies on Memory https://brand.kioxia.com/en-jp/articles/article25.html
Memory-Centric AI, Part II: An Internet of Memories: Brainstorming Uses for Memory-Centric AI https://brand.kioxia.com/en-jp/articles/article26.html

About ECCV

The European Conference on Computer Vision (ECCV) is one of the top conferences in the field of computer vision. In recent years, ECCV has established itself as a prime venue for the presentation of AI research papers including image classification, object detection, and other technologies using deep learning. The oral presentation acceptance rate was 2.7% in this year.

[1] Paper title: K. Nakata et. al., “Revisiting a kNN-based Image Classification System with High-capacity Storage”, European Conference on Computer Vision 2022 (ECCV 2022)
[2] Image feature maps: multidimensional (e.g., 1,024-dimensional) numerical data obtained through neural network operations
[3] Explainability of AI: possibly of explaining the basis and reasons of results predicted by AI in a way that can be interpreted by humans.
[4] Black-box problem: the process leading to the results predicted by AI is not interpretable to humans, making it a black box problem.

Company names, product names, and service names may be trademarks of third-party companies.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006375/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye